Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ayala Pharmaceuticals, Inc.ADXS · Entity 93434 | Chief Financial Officer | October 18, 2023 | November 03, 2023 |
| My Size, Inc.MYSZ · Entity 8556 | Director | December 15, 2025 | December 17, 2025 |
| NeuroSense Therapeutics Ltd.NRSN · Entity 7767 | Director | March 18, 2026 | March 18, 2026 |
| Old Ayala, IncADXS · Entity 108681 | Chief Financial Officer | October 18, 2023 | October 31, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ayala Pharmaceuticals, Inc.
Report date October 18, 2023 · Filed November 03, 2023 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
This filing explicitly reported no securities owned.
My Size, Inc.
Report date December 15, 2025 · Filed December 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,000 |
Reported balance
After 2025-12-15 transaction · row 1
1 source rowRow 1 · 2025-12-15 · Grant · Acquired 15,000 · Balance 15,000 F1: Restricted shares granted under the My Size, Inc. 2017 Equity Incentive Plan. F2: The restricted shares vest on December 31, 2025, subject to the Reporting Person's continued service to the Issuer as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted shares granted under the My Size, Inc. 2017 Equity Incentive Plan.
F2: The restricted shares vest on December 31, 2025, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
NeuroSense Therapeutics Ltd.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 24,000 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 24,000 F1: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 60,000 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 60,000 F1: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee. F2: These restricted shares vest on December 30, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 76,844 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 76,844 F1: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee. F3: These restricted shares vest on January 30, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee.
F2: These restricted shares vest on December 30, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
F3: These restricted shares vest on January 30, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
Old Ayala, Inc
Report date October 18, 2023 · Filed October 31, 2023
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2025 Filed Dec 17, 2025 21:15 UTC | My Size, Inc. MYSZ · Entity 8556 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-028143 · ownership.xml · nonDerivative · entry 1 Golan Roy · CIK 0001999257 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Restricted shares granted under the My Size, Inc. 2017 Equity Incentive Plan. F2 · shares: The restricted shares vest on December 31, 2025, subject to the Reporting Person's continued service to the Issuer as of such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.